Summary of estimated hazard ratios
| Model term . | P . | HR . | HR lower 95% . | HR upper 95% . |
|---|---|---|---|---|
| D−/R+ recipient | .009 | 1.8 | 1.2 | 2.9 |
| GVHD, grade II+ | .0015 | 2.1 | 1.3 | 3.3 |
| Propensity score, IQR units, for pre-HCT covariates | .6 | 1.1 | NA | NA |
| Model term . | P . | HR . | HR lower 95% . | HR upper 95% . |
|---|---|---|---|---|
| D−/R+ recipient | .009 | 1.8 | 1.2 | 2.9 |
| GVHD, grade II+ | .0015 | 2.1 | 1.3 | 3.3 |
| Propensity score, IQR units, for pre-HCT covariates | .6 | 1.1 | NA | NA |
Summary of results of a proportional hazards regression model for the hazard of requiring initial or recurrent antiviral therapy. Adjustment for baseline covariates is accomplished by inclusion of the propensity score, which is scaled to its interquartile range (IQR units) so that the estimated hazard ratio (HR) represents the effect of typical variation in baseline covariates. Methods for calculating P values can be found in “Statistical methods.”
NA indicates not applicable.